D
deleted87716
A 2009 trial published in NEJM compared ezetimibe + statin to extended-release niacin + statin. Both lowered LDL. Niacin reduced artery wall thickness, but ezetimibe increased artery wall thickness. Bad news.
ARBITER 6-HALTS was really a pretty mediocre study.
The study was supported by Abbott, the maker of Niaspan. It was not powered or designed to investigate major cardiac events. It was a small study. Only 208 patients finished after 14 months because it was terminated prematurely, possibly giving Niaspan an advantage. Patients on Niaspan were taking 2 grams a day (if you can get your patients to tolerate 2 grams per day without flushing, God bless you). Patients enrolled in the study already had very low LDL (most <100, hardly your typical patients). The Zetia arm showed greater LDL reductions than the Niaspan arm.
I'd be hesitant to draw any firm conclusions from this trial.
More info here: http://www.medpagetoday.com/MeetingCoverage/AHA/17067
Last edited by a moderator: